AI Article Synopsis
Article Abstract
The CYP2D6 enzyme is involved in the metabolism of numerous psychopharmacological drugs. Guidelines recommend how to adjust the dose of medication based on the genotype. To evaluate the effect of dose adjustment to the genotype and phenotype, in patients with severe mental illness (SMI) already receiving psychopharmacological treatment. A total of 269 psychiatric patients (on the island Curaçao) receiving antipsychotic treatment were genotyped for . Of these, 45 patients were included for dose adjustment according to the clinical guideline of the Royal Dutch Association for the Advancement of Pharmacy, i.e., 17 CYP2D6 poor metabolizers, 26 intermediate metabolizers, and 2 ultrarapid metabolizers. These 45 patients were matched for age, gender, and type of medication with a control group of 41 patients who were CYP2D6 extensive metabolizers (i.e., with a normal CYP2D6 function). At baseline and at 4 months after dose adjustment, subjective experience, psychopathology, extrapyramidal side-effects, quality of life, and global functioning were assessed in these two groups. At baseline, there were no differences between the groups regarding the prescribed dosage of antipsychotics, the number of side-effects, psychiatric symptoms, global functioning, or quality of life. After dose adjustment, no significant improvement in these parameters was reported. In psychiatric patients with SMI already receiving antipsychotic treatment, dose adjustment to the genotype or phenotype according to the guidelines showed no beneficial effect. This suggests that dose adjustment guidelines are currently not applicable for patients already using antipsychotics. ClinicalTrials.gov: Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao; Identifier: NCT02713672; https://clinicaltrials.gov/ct2/show/NCT02713672?term=CYP2D6&rank=5.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090167 | PMC |
| http://dx.doi.org/10.3389/fpsyt.2018.00349 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous iron sucrose when administered to moderately anemic pregnant women raises the hemoglobin concentration and replenishes body iron at 6 months.
J Family Med Prim Care
November 2024
Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India.
Introduction: Intravenous iron sucrose (IVIS) is a rapidly acting, safe, and effective treatment for moderate anemia among pregnant women. The effectiveness of IVIS at 6 months post IVIS infusion was unknown. We, therefore, assessed the mean increase in hemoglobin concentration and body iron replenishment status at 6 months after the last dose of IVIS infusion.
View Article and Find Full Text PDFOutbreak of cholera in the Southwest region of Cameroon, 2021-22: an epidemiological investigation.
BMC Public Health
December 2024
Institute of Tropical Medicine Antwerp, Nationalestraat 155, 2000, Antwerp, Belgium.
Background: In October 2021, a large outbreak of cholera was declared in Cameroon, disproportionately affecting the Southwest region, one of 10 administrative regions in the country. In this region, the cases were concentrated in three major cities where a humanitarian crisis had concomitantly led to an influx of internally displaced persons. Meanwhile, across the border, Nigeria was facing an unprecedented cholera outbreak.
View Article and Find Full Text PDFCorticosteroid therapy for treating acute exacerbation of interstitial lung diseases: a systematic review.
Thorax
December 2024
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Introduction: Acute exacerbation of interstitial lung disease (AE-ILD) often results in death and poses significant challenges in clinical management. While corticosteroids are frequently employed, the optimal regimen and their clinical efficacy remain uncertain. To address this knowledge gap, we undertook a systematic review to evaluate the impact of steroid therapy on clinical outcomes in patients experiencing AE-ILD.
View Article and Find Full Text PDFCorticosteroid dose escalation in non-ICU COVID-19 patients with worsening lung lesions reduces lesion severity without improving clinical outcomes.
Drug Discov Ther
December 2024
Department of Infectious Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
The effect of increasing corticosteroid doses on clinical outcomes and chest findings in patients with coronavirus disease (COVID-19) pneumonia and lung disease remains unknown. We aimed to investigate the effects of increasing steroid dosage on chest lesion area and clinical outcomes in patients with moderate or severe COVID-19 and progressive lung involvement on chest computed tomography (CT). A total of 105 patients with radiological progression during methylprednisolone (MP) therapy either received an increased MP dose (n = 79) or were maintained on the same MP dose (n = 26).
View Article and Find Full Text PDFConcordance-based Predictive Uncertainty (CPU)-Index: Proof-of-concept with application towards improved specificity of lung cancers on low dose screening CT.
Artif Intell Med
December 2024
Department of Electrical and Computer Engineering, Duke University, Durham, NC, United States of America; Medical Physics Graduate Program, Duke University, Durham, NC, United States of America; Department of Radiology, Duke University, Durham, NC, United States of America; Department of Biomedical Engineering, Duke University, Durham, NC, United States of America; Department of Radiation Oncology, Duke University, Durham, NC, United States of America; Department of Pathology, Duke University, Durham, NC, United States of America. Electronic address:
In this paper, we introduce a novel concordance-based predictive uncertainty (CPU)-Index, which integrates insights from subgroup analysis and personalized AI time-to-event models. Through its application in refining lung cancer screening (LCS) predictions generated by an individualized AI time-to-event model trained with fused data of low dose CT (LDCT) radiomics with patient demographics, we demonstrate its effectiveness, resulting in improved risk assessment compared to the Lung CT Screening Reporting & Data System (Lung-RADS). Subgroup-based Lung-RADS faces challenges in representing individual variations and relies on a limited set of predefined characteristics, resulting in variable predictions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!